Advancements in Gastroenterology: A Weekly Review
Gastroenterologia
Gastroenterology Breakthroughs: From Gut Microbiome to Precision Oncology
This week's episode explores groundbreaking research in gastroenterology, from microbiome therapies and IBD management to precision oncology approaches in GI cancers. We discuss probiotic guidelines, gut barrier function, and AI diagnostics alongside exciting developments in HER2-positive gastric cancer and cholangiocarcinoma treatments.
Bibliography
1. When probiotics guidelines differ: a practical guide for clinicians and researchers.
Authors: Preidis GA, Szajewska H, Cunningham M, et al.
Journal: Gut microbes, 2026 Dec 31
PMID: 41986915
DOI: 10.1080/19490976.2026.2657049
2. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.
Authors: Janjigian YY, Kawazoe A, Yañez P, et al.
Journal: Nature, 2021 Dec
PMID: 34912120
DOI: 10.1038/s41586-021-04161-3
3. The Efficacy of Probiotics, Prebiotics, Synbiotics, and Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis.
Authors: Wu Y, Li Y, Zheng Q, et al.
Journal: Nutrients, 2024 Jul 2
PMID: 38999862
DOI: 10.3390/nu16132114
4. Ulcerative colitis.
Authors: Ungaro R, Mehandru S, Allen PB, et al.
Journal: Lancet (London, England), 2017 Apr 29
PMID: 27914657
DOI: 10.1016/S0140-6736(16)32126-2
5. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.
Authors: Janjigian YY, Kawazoe A, Yañez P, et al.
Journal: Nature, 2021 Dec
PMID: 34912120
DOI: 10.1038/s41586-021-04161-3
6. Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer.
Authors: Ma L, Hernandez MO, Zhao Y, et al.
Journal: Cancer cell, 2019 Oct 14
PMID: 31588021
DOI: 10.1016/j.ccell.2019.08.007
7. Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review.
Authors: Di Vincenzo F, Del Gaudio A, Petito V, et al.
Journal: Internal and emergency medicine, 2024 Mar
PMID: 37505311
DOI: 10.1007/s11739-023-03374-w
8. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 Update.
Authors: Maillard M, Schwab M, Whirl-Carrillo M, et al.
Journal: Clinical pharmacology and therapeutics, 2026 Apr
PMID: 41618934
DOI: 10.1002/cpt.70209
9. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Authors: Abou-Alfa GK, Macarulla T, Javle MM, et al.
Journal: The Lancet. Oncology, 2020 Jun
PMID: 32416072
DOI: 10.1016/S1470-2045(20)30157-1
10. A rural-to-center artificial intelligence model for diagnosing Helicobacter pylori infection and premalignant gastric conditions using endoscopy images captured in routine practice.
Authors: Chiang TH, Hsu YN, Chen MH, et al.
Journal: Endoscopy, 2026 Apr
PMID: 41082919
DOI: 10.1055/a-2721-6552
Authors: Preidis GA, Szajewska H, Cunningham M, et al.
Journal: Gut microbes, 2026 Dec 31
PMID: 41986915
DOI: 10.1080/19490976.2026.2657049
2. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.
Authors: Janjigian YY, Kawazoe A, Yañez P, et al.
Journal: Nature, 2021 Dec
PMID: 34912120
DOI: 10.1038/s41586-021-04161-3
3. The Efficacy of Probiotics, Prebiotics, Synbiotics, and Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis.
Authors: Wu Y, Li Y, Zheng Q, et al.
Journal: Nutrients, 2024 Jul 2
PMID: 38999862
DOI: 10.3390/nu16132114
4. Ulcerative colitis.
Authors: Ungaro R, Mehandru S, Allen PB, et al.
Journal: Lancet (London, England), 2017 Apr 29
PMID: 27914657
DOI: 10.1016/S0140-6736(16)32126-2
5. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.
Authors: Janjigian YY, Kawazoe A, Yañez P, et al.
Journal: Nature, 2021 Dec
PMID: 34912120
DOI: 10.1038/s41586-021-04161-3
6. Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer.
Authors: Ma L, Hernandez MO, Zhao Y, et al.
Journal: Cancer cell, 2019 Oct 14
PMID: 31588021
DOI: 10.1016/j.ccell.2019.08.007
7. Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review.
Authors: Di Vincenzo F, Del Gaudio A, Petito V, et al.
Journal: Internal and emergency medicine, 2024 Mar
PMID: 37505311
DOI: 10.1007/s11739-023-03374-w
8. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 Update.
Authors: Maillard M, Schwab M, Whirl-Carrillo M, et al.
Journal: Clinical pharmacology and therapeutics, 2026 Apr
PMID: 41618934
DOI: 10.1002/cpt.70209
9. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Authors: Abou-Alfa GK, Macarulla T, Javle MM, et al.
Journal: The Lancet. Oncology, 2020 Jun
PMID: 32416072
DOI: 10.1016/S1470-2045(20)30157-1
10. A rural-to-center artificial intelligence model for diagnosing Helicobacter pylori infection and premalignant gastric conditions using endoscopy images captured in routine practice.
Authors: Chiang TH, Hsu YN, Chen MH, et al.
Journal: Endoscopy, 2026 Apr
PMID: 41082919
DOI: 10.1055/a-2721-6552
